Board Meeting Intimation for Results
Merck Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 11, 2016, inter alia, to consider and approve the un-audited financial results for the period and quarter ended September 30, 2016. Shareholding for the Period Ended September 30, 2016
Merck Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Merck Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Merck directors Brijesh Kapil and Ali Sleiman resign
Drug firm Merck Ltd today said its whole time directors Brijesh Kapil and Ali Sleiman have resigned from the board.Recently, Merck implemented certain organisational changes which impacted the roles... Change in Directorate
Merck Ltd has informed BSE that recently Merck has implemented certain organisation changes which impact the roles and responsibilities of two whole time directors, viz. Mr. Brijesh Kapil and Mr. Ali Sleiman. As such Mr. Brijesh Kapil and Ali Sleiman, whole time directors, have expressed their inability to continue as directors on the Board of the Company and have tendered their resignation from the office of director of the Company effective from... Closure of Trading Window
Merck Ltd has informed BSE that the Company has already issued notification to its employees on September 12, 2016 regarding closure of trading window for them for the purposes of consideration and approval of the un-audited financial results from September 15, 2016 until 24 hours from the publication of the un-audited financial results for the quarter to be ended on September 30, 2016. The Company would be subsequently informing the date of the... Updates
Merck Ltd has informed BSE regarding "SEBI Order in the matter of Sharepro Services (I) Pvt. Ltd.". Merck's Indian unit MSD may sell primary care drugs to focus on core brands
A sizeable part of the divestiture is from the primary care segment with a few Indian drug makers showing interest. Valuation is, however, posing obvious challenges. Breakthrough cancer drugs all set for India launch
MUMBAI: Cancer patients in India are set to gain faster access to two of the world's best known new generation drugs - Keytruda from US based Merck and Bristol Myer Squibb's Opdivo - both used to treat melanoma, a form of malignant skin cancer and a life-threatening lung cancer. According to a top health ministry official, while Keytruda has recently been granted approval by the Drug Controller General of India in line with recommendations of expert oncologists and a powerful apex committee, Opdivo has secured waiver from clinical trials a few months ago, paving the way for its marketing authorization. The accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by the end of the year, market sources indicated. Ever since their approvals by the US FDA in 2014, the two drugs have set new standards in cancer care, raising hopes of more breakthroughs in managing cancer patients. While most existing drugs aggressively attack cancer cells and in the process risk harming healthy tissues, Keytruda and Opdivo work differently, helping the immune system identify and selectively combat only the cancerous cells. While Keytruda generated global sales of $566 million during 2015, Opdivo grossed $942 million, on course to reaching a blockbuster status. Last November, a Subject Expert Committee (SEC) in India had granted import and marketing for pembrolizumab, branded Keytruda. It said the drug may be granted waiver of local clinical trial but put a condition of conducting phase four study in Indian patients. Standalone Financial Results, Limited Review Report for June 30, 2016
Merck Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Standalone Limited Review for the period ended June 30, 2016